Kindred Biosciences Announces Positive Results from Pilot Field Efficacy Study of its IL-4/IL-13 SINK Molecule Being Developed for the Treatment of Atopic Dermatitis in Dogs

March 24, 2020

SAN FRANCISCO , March 24, 2020 /PRNewswire/ --  Kindred Biosciences, Inc. (NASDAQ...

Kindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction and Reports Fourth Quarter and Full Year 2019 Financial Results

March 16, 2020

SAN FRANCISCO , March 16, 2020 /PRNewswire/ --  Kindred Biosciences, Inc. (NASDAQ...

Kindred Biosciences to Announce Fourth Quarter and Year-End 2019 Financial Results

March 3, 2020

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. P...

Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit

February 18, 2020

SAN FRANCISCO , Feb. 18, 2020 /PRNewswire/ --  Kindred Biosciences, Inc.  (NASDAQ...

Kindred Biosciences Announces Half-Life Extension Technology for Canine Antibodies

January 8, 2020

- Positive results from canine pharmacokinetic study demonstrate up to three-fold...